Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Payables (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Payables for 6 consecutive years, with $57.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Payables rose 86.05% to $57.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $57.6 million, a 86.05% increase, with the full-year FY2025 number at $57.6 million, up 86.05% from a year prior.
  • Payables was $57.6 million for Q4 2025 at GeneDx Holdings, up from $50.3 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $115.9 million in Q2 2022 to a low of $31.0 million in Q4 2024.
  • A 5-year average of $55.2 million and a median of $49.8 million in 2025 define the central range for Payables.
  • Peak YoY movement for Payables: soared 223815.85% in 2021, then plummeted 55.87% in 2023.
  • GeneDx Holdings' Payables stood at $44.7 million in 2021, then surged by 89.91% to $84.9 million in 2022, then plummeted by 55.87% to $37.5 million in 2023, then dropped by 17.28% to $31.0 million in 2024, then soared by 86.05% to $57.6 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's Payables are $57.6 million (Q4 2025), $50.3 million (Q3 2025), and $49.2 million (Q2 2025).